Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study

[1]  A. Alencar,et al.  Oral Abstract: MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study , 2022, Clinical Lymphoma Myeloma and Leukemia.

[2]  Youyou Yan,et al.  Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical , 2022, Drug design, development and therapy.

[3]  P. Zinzani,et al.  Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement , 2022, Hematological oncology.

[4]  Wei Jiang,et al.  Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203) , 2021, Blood.

[5]  I. Lossos,et al.  Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204) , 2021, Blood.

[6]  J. Byrd,et al.  Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Michael L. Wang,et al.  Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study , 2021, The Lancet.

[8]  T. Phillips,et al.  Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma? , 2020, Clinical lymphoma, myeloma & leukemia.

[9]  M. Dimopoulos,et al.  A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY. , 2020, Blood.

[10]  H. Koblish,et al.  Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy , 2020, The Journal of Pharmacology and Experimental Therapeutics.

[11]  H. Koblish,et al.  INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ). , 2019, ACS medicinal chemistry letters.

[12]  A. Zelenetz,et al.  Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse , 2019, Blood Cancer Journal.

[13]  D. Demarini,et al.  Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. , 2019, Blood.

[14]  I. Flinn,et al.  DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Novotny,et al.  Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial , 2018, Blood.

[16]  M. Talpaz,et al.  Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. , 2018, Blood.

[17]  Michael L. Wang,et al.  Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[18]  G. Lenz,et al.  Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Vose.  Mantle cell lymphoma: 2017 update on diagnosis, risk‐stratification, and clinical management , 2017, American journal of hematology.

[20]  Michael L. Wang,et al.  Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. , 2015, Blood.

[21]  C. Flowers,et al.  New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy , 2015, Expert review of anticancer therapy.

[22]  Jean J. Zhao,et al.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting , 2014, Nature Reviews Cancer.

[23]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Byrd,et al.  A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). , 2014, Blood.

[25]  G. Salles,et al.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.

[26]  M. Ladetto,et al.  Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  L. Tanoue,et al.  The National Comprehensive Cancer Network , 1998, Cancer.